Table 4 Annual percentage change for breast cancer stage groups by receptor-based subtype, SEER 17 registries, 2010–2021
HR+/HER2− | HR+/HER2+ | TNBC | HR−/HER2+ | |||||
|---|---|---|---|---|---|---|---|---|
N | APC (95% CI) | N | APC (95% CI) | N | APC (95% CI) | N | APC (95% CI) | |
All diagnoses | 486,031 | 0.6 (−0.1, 1.4) | 78,885 | −3.8 (−6.4, −1.2) | 67,624 | −0.9 (−1.7, −0.2) | 27,911 | −3.1 (−5.0, −1.1) |
N2-3M0 (Any T) | 28,585 | −3.5 (−4.3, −2.8) | 6223 | −8.4 (−11.8, −4.9) | 5785 | −5.6 (−6.8, −4.3) | 2767 | −10.3 (−12.9, −7.6) |
T3-4N0-1M0 | 23,307 | 1.7 (0.9, 2.5) | 5898 | −1.4 (−4.2, 1.5) | 6293 | 0.2 (−1.2, 1.5) | 3244 | −0.8 (−3.2, 1.6) |
N0M0 (Any T) | 359,405 | 1.0 (0.2, 1.9) | 52,377 | −3.8 (−6.7, −0.8) | 46,337 | −0.5 (−1.3, 0.3) | 17,117 | −2.9 (−5.1, −0.6) |
N1M0 (Any T) | 97,853 | 0.4 (−0.2, 1.1) | 20,201 | −2.2 (−4.0, −0.4) | 15,457 | −0.4 (−1.4, 0.7) | 7987 | −0.9 (−2.6, 0.8) |
